Mobidiag Revenue and Competitors
Estimated Revenue & Valuation
- Mobidiag's estimated annual revenue is currently $19.5M per year.
- Mobidiag's estimated revenue per employee is $155,000
Employee Data
- Mobidiag has 126 Employees.
- Mobidiag grew their employee count by -8% last year.
Mobidiag's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | R & D Director | Reveal Email/Phone |
3 | Senior Director, Quality & Regulatory | Reveal Email/Phone |
4 | Customer Support Manager | Reveal Email/Phone |
5 | R&D Manager | Reveal Email/Phone |
6 | R&D Manager | Reveal Email/Phone |
7 | Senior R&D Manager | Reveal Email/Phone |
8 | R&D Manager, qPCR Products | Reveal Email/Phone |
9 | Quality Control Manager | Reveal Email/Phone |
10 | Financial Manager | Reveal Email/Phone |
Mobidiag Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $7.7M | 61 | 20% | N/A | N/A |
What Is Mobidiag?
Mobidiag is a biotechnology company specialized in development and commercialization of molecular diagnostics solutions used by clinical laboratories for detection of infectious diseases, including antibiotic resistances. Following the strategic and successful corporate three-way merger in 2013, complementing technologies and products were brought together to answer customer needs in the field of infectious disease diagnostics. Currently, Mobidiag offers 2 product lines: - the Amplidiag® solution, a qPCR-based multiplex based product line comprising the Amplidiag® Easy automated platform and a large panel of gastrointestinal disease tests for semi-automation of overall lab workflow. The Amplidiag products target large laboratories with high volume screening requirements. - the innovative Novodiag®, a fully automated molecular diagnostics solution for both syndromic and targeted testing of infectious diseases. Novodiag is particularly well suited for small to medium-sized laboratories as well as decentralized labs thanks to its simple on-demand capacity. As a result, combining both Amplidiag and Novodiag solutions, Mobidiag covers all microbiology laboratories requirements no matter their size, throughput and centralized/decentralized organization. Follow us on LinkedIn, Twitter, Facebook and Instagram for daily updates! According to the latest GDPR requirements, visit our privacy policy page to learn more about how we collect your data and feel free to contact us if needed at marketing@mobidiag.com: http://mobidiag.com/assets/uploads/2018/05/mobidiag-privacy-policy.pdf
keywords:N/A
N/A
Total Funding
126
Number of Employees
$19.5M
Revenue (est)
-8%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Mobidiag News
Mobidiag Ltd., an Espoo, Finland-based revenue generating, molecular diagnostics company with complementary platforms that address antimicrobial resistance and other areas of unmet diagnostic need, received a EUR 1.5 million (~$1.65m) additional funding. The company intends to use the funds for ...
Tuomas Tenkanen, CEO of Mobidiag, said “We are excited to further expand our commercial footprint into Africa, which represents a fast ...
NEW YORK (GenomeWeb) – Mobidiag said today that it has launched a joint venture with Autobio Diagnostics, a leading Chinese clinical ...
Molecular diagnostics company Mobidiag has received an EIB loan to accelerate the development and commercialisation of its in vitro ...
Mobidiag Ltd., an Espoo, Finland-based commercial stage molecular diagnostics company addressing the spread of antimicrobial resistance, completed a €10m equity investment. Autobio Diagnostics made the investment. The company intends to use the funds to continue growing its product portfolio, ...
Other Companies in Espoo
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $18.9M | 130 | 20% | N/A |
#2 | $29M | 132 | 23% | N/A |
#3 | $27.3M | 133 | -10% | N/A |
#4 | $32.8M | 134 | 5% | N/A |
#5 | $20.3M | 135 | 0% | N/A |